Michael Basista, MD
Gastroenterology · Sylvania, OHNPI 1548257876
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $106,956 of the $132,175 with a category attached, or 80.9%. 35 manufacturers reported payments, led by Gilead at 57.1% of the total. Among gastroenterology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 828 payments — averaging $159.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$76K
- Madrigal Pharmaceuticals$37K
- AbbVie$13K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$996
- Johnson & Johnson$541
- plus $3K from 29 others
Across 25 payments — averaging $3215.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$69K
- Janssen Research & Development, LLC$11K
What the payments were for
- Speaking & faculty fees$106,95681%
- Travel & lodging$11,7989%
- Food & beverage$13,40110%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 183 | $75,503 |
| Madrigal Pharmaceuticals | 38 | $37,441 |
| AbbVie(2 entities) | 220 | $13,112 |
| Takeda Pharmaceuticals U.S.A., Inc. | 120 | $1,765 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 78 | $996 |
| Johnson & Johnson | 40 | $541 |
| Sanofi | 19 | $442 |
| Aimmune Therapeutics, Inc. | 22 | $343 |
| Pfizer | 19 | $304 |
| Phathom Pharmaceuticals, Inc. | 13 | $241 |
| Nestle Healthcare Nutrition Inc. | 9 | $152 |
| QOL Medical, LLC | 7 | $134 |
| Ardelyx, Inc. | 7 | $127 |
| Mallinckrodt Hospital Products Inc. | 1 | $127 |
| Intercept Pharmaceuticals, Inc. | 5 | $126 |
| Daiichi Sankyo Inc. | 5 | $92 |
| Merck | 5 | $88 |
| Bristol Myers Squibb | 4 | $70 |
| Shire North American Group Inc | 4 | $57 |
| Ipsen Biopharmaceuticals, Inc | 3 | $56 |
| Lilly USA, LLC | 2 | $53 |
| Ferring Pharmaceuticals Inc. | 2 | $50 |
| Boston Scientific | 2 | $45 |
| Braintree Laboratories, Inc. | 3 | $45 |
| Shionogi Inc | 3 | $41 |
| Organon | 2 | $33 |
| Regeneron Healthcare Solutions, Inc. | 2 | $32 |
| Ironwood Pharmaceuticals, Inc | 2 | $28 |
| Alfasigma USA, Inc. | 2 | $26 |
| Novo Nordisk | 1 | $23 |
| Celltrion USA Inc. | 1 | $20 |
| Medtronic | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Redhill Biopharma Inc. | 1 | $14 |
| Amgen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$132,175 in reported general payments places this provider in the 95th percentile of 657 gastroenterology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 57 | $1,570,931 |
| XifaxanRifaximin | 34 | $102,410 |
| CreonLipase/Protease/Amylase | 35 | $85,976 |
| LinzessLinaclotide | 62 | $51,220 |
| Alosetron Hcl | 22 | $29,434 |
| VemlidyTenofovir Alafenamide | 20 | $28,564 |
| Mesalamine | 35 | $23,549 |
| ViberziEluxadoline | 11 | $17,329 |
| MotegrityPrucalopride Succinate | 14 | $10,845 |
| Ursodiol | 34 | $8,377 |
| Pantoprazole Sodium | 402 | $6,667 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 90 | $5,276 |
| Esomeprazole Magnesium | 67 | $3,840 |
| Budesonide DrBudesonide | 22 | $3,390 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 16 | $2,707 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $541 | $1,570,93157 claims |
| AbbVieCreon, Linzess, Viberzi | $13,112 | $154,525108 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $996 | $102,41034 claims |
| GileadVemlidy | $75,503 | $28,56420 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $1,765 | $10,84514 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $50 | $2,70716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 657 gastroenterology providers in Ohio.
Other gastroenterology in Sylvania
- Thomas ColturiSylvania$109K
- Naim AlkhouriWestlake$1.9M
- Pierre GholamCleveland$1.6M
- Anita AfzaliCincinnati$798K
- Mohamed NaemWestlake$708K
- Kara de FeliceCincinnati$427K
- Tasos ManokasColumbus$411K
- Florian RiederCleveland$396K
- Allan PeckCincinnati$391K
- Dany RaadHighland Hills$387K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.